Drug intelligence / Profile preview

n-oleoyldopamine

Development stage: Unknown
Modality: Small Molecules

Overview

N-Oleoyldopamine (OLDA) is an endogenous lipid metabolite formed by the condensation of oleic acid and dopamine. It acts as a selective agonist for the transient receptor potential vanilloid type 1 (TRPV1), also known as the vanilloid receptor 1 (VR1). OLDA is found in mammalian brain tissue and has been shown to modulate activity of midbrain dopaminergic neurons through multiple mechanisms. It is equipotent to capsaicin at TRPV1 receptors and can induce hyperalgesia and nocifensive behavior in animal models. Additionally, OLDA is a potent inhibitor of 5-lipoxygenase[6][7][4].

Other names: N-oleoyl-dopamine(9Z)-N-[2-(3,4-dihydroxyphenyl)ethyl]octadec-9-enamideN-[2-(3,4-dihydroxyphenyl)ethyl]-9Z-octadecenamide

Targets

ALOX12 (Arachidonate 12-lipoxygenase, 12S type)TRPV1 (Transient receptor potential cation channel subfamily V member 1)

Beyond the preview

Go deeper on n-oleoyldopamine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on n-oleoyldopamine.

Explore the full profile